Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company's rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococcal A, C, Y and W-135 conjugate vaccine are in phase I. Its Serogroup B meningococcal outer membrane vesicle, 20-valent pneumococcal polysaccharide conjugate, recombinant zoster vaccine, multivalent HFMD (hand foot and mouth disease), high-dose influenza, and inactivated rabies monoclonal antibody vaccine are in the pre-clinical stage. Liaoning Chengda Biotechnology Co.,Ltd. was founded in 2002 and is headquartered in Shenyang, China. Liaoning Chengda Biotechnology Co.,Ltd. is a subsidiary of Liaoning Cheng Da Co., Ltd.